Quoin reports positive interim Phase 2/3 data for QRX003 in Netherton syndrome trial

PUBT · 2d ago
Quoin reports positive interim Phase 2/3 data for QRX003 in Netherton syndrome trial
  • Quoin Pharmaceuticals posted interim Phase 2/3 results for QRX003 lotion in Netherton syndrome, based on the first six patients.
  • The analysis showed a meaningful share of patients improved on clinician-rated skin assessments, supporting the product’s efficacy signal.
  • Patients also reported improvement in itch, pointing to potential symptomatic benefit alongside physician-assessed changes.
  • No treatment-related serious safety issues were reported, reducing near-term clinical and regulatory risk for the program.
  • Full enrollment is targeted by end-2026, with topline results expected in Q2 2027, a key catalyst for the stock.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608280600PRIMZONEFULLFEED9817432) on August 28, 2026, and is solely responsible for the information contained therein.